Home/Filings/4/0001437749-25-030665
4//SEC Filing

Danahy Kevin Patrick 4

Accession 0001437749-25-030665

CIK 0001625101other

Filed

Oct 6, 8:00 PM ET

Accepted

Oct 7, 7:18 PM ET

Size

9.0 KB

Accession

0001437749-25-030665

Insider Transaction Report

Form 4
Period: 2025-10-02
Danahy Kevin Patrick
Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-10-02$1.53/sh+4,600$7,03847,898 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-10-024,600425,000 total
    Exercise: $1.53Exp: 2032-09-23Common Stock (4,600 underlying)
  • Sale

    Common Stock

    2025-10-02$18.53/sh4,600$85,23843,298 total
Footnotes (3)
  • [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 14, 2025.
  • [F2]The price in column 4 is the weighted average price per share sold. The price per share actually received by the reporting person ranged from $18.48 to $18.65 per share. For all transactions reported in this Form 4 using a weighted average price, the reporting person undertakes upon request by the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price within the range.
  • [F3]Options granted on September 23, 2022, to acquire up to 450,000 shares of Common Stock, in connection with reporting person's promotion, with 25% vesting on each anniversary of grant, pursuant to the terms of an amendment to reporting person's Employment Agreement dated February 9, 2022.

Issuer

PULSE BIOSCIENCES, INC.

CIK 0001625101

Entity typeother

Related Parties

1
  • filerCIK 0001913245

Filing Metadata

Form type
4
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 7:18 PM ET
Size
9.0 KB